Dr. Read is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd Nw
Washington, DC 20007Phone+1 202-444-8830
Education & Training
- MedStar Health/Georgetown University HospitalFellowship, Pulmonary Disease and Critical Care Medicine, 1988 - 1991
- Georgetown University School of MedicineClass of 1985
Certifications & Licensure
- VA State Medical License 1987 - 2024
- DC State Medical License 1991 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Publications & Presentations
PubMed
- 1048 citationsCyclophosphamide versus placebo in scleroderma lung disease.Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Jonathan G. Goldin, Michael D. Roth
The New England Journal of Medicine. 2006-06-22 - 295 citationsEffects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Michael D. Roth, Daniel E. Furst
American Journal of Respiratory and Critical Care Medicine. 2007-11-15 - 499 citationsMycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P. Tashkin, Michael D. Roth, Philip J. Clements, Daniel E. Furst, Dinesh Khanna
The Lancet. Respiratory Medicine. 2016-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: